Understanding the Mode of Action of a Micro-Immunotherapy Formulation: Pre-Clinical Evidence from the Study of 2LEBV^® Active Ingredients.

ABSTRACT:

Background

Epstein-Barr virus (EBV) is often kept silent and asymptomatic; however, its reactivation induces a chronic and/or recurrent infection that is associated with numerous diseases, including cancer and inflammation-related disorders. As no specific treatment is currently available, the immune factors-based micro-immunotherapy (MI) medicine 2LEBV^® could be considered a valuable therapeutic option to sustain the immune system in EBV reactivation.

Methods

The present work aimed to investigate, for the first time, the effect of 2LEBV^® in several in vitro models of uninfected immune-related cells.

Results

2LEBV^® displayed phagocytosis-enhancing capabilities in granulocytes. In human peripheral blood mononuclear cells (PBMCs), it inc

SUBMITTER: Jacques C 

PROVIDER: S-EPMC10821216 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature